Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients

F. van Delft, E. Koffijberg, V. Retel, M. Schuurbiers, H. van Rossum, M. van den Heuvel, M. IJzerman

Research output: Contribution to journalArticleAcademic

Abstract


Immunotherapy is known to provide a substantial survival benefit to a select group of non-small cell lung cancer (NSCLC) patients, therefore, early identification of progression provides a more beneficial treatment to these patients. Serum tumor markers can be used to monitor the response to treatment, however no clear guidance is available how to use and interpret their longitudinal results. Our study aims to evaluate and compare longitudinal biomarker analysis methods, in early detection of progressive disease in immunotherapy treated NSCLC patients.
Original languageEnglish
Article numberPCN279
Pages (from-to)S472-S472
JournalValue in health
Volume23
Issue numberSuppl. 2
DOIs
Publication statusPublished - Dec 2020

Fingerprint Dive into the research topics of 'Comparing Methods of Longitudinal SERUM Tumor Marker Analisis in Response Monitoring of Immunotherapy Treated NON-SMALL Cell LUNG Cancer Patients'. Together they form a unique fingerprint.

Cite this